The Zurich-based company is an ETH Zurich spin-off focused on the development of novel genetic medicines for rare diseases with high unmet medical need. The company is pioneering a new therapeutic platform that combines hematopoietic stem cells with CRISPR-Cas9 gene editing to enable precise and durable genetic modifications within blood stem cells.